Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-02T19:40:55.520Z.
Calculation as of: 2026-10-02T19:40:55.520Z.
Quote observation: 2026-10-02T19:40:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a42e17afc1a1b5c0c05c4bcc318afc1e85bdb01f5d7a677422ba224d703768eb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Recursion Pharmaceuticals, Inc.
Market Cap
$2.14B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.51B
Price/FCF Ratio
N/A
TTM Avg
44.80
3Y Avg
44.80
5Y Avg
44.80
Market Cap
$1.73B
Price/FCF Ratio
12.08
TTM Avg
22.94
3Y Avg
20.46
5Y Avg
20.08
Market Cap
$1.72B
Price/FCF Ratio
N/A
TTM Avg
13.58
3Y Avg
13.58
5Y Avg
13.58
Market Cap
$2.74B
Price/FCF Ratio
34.64
TTM Avg
55.51
3Y Avg
87.60
5Y Avg
87.60
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | $2.14B | N/A | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.51B | N/A | 44.80 | 44.80 | 44.80 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | 12.08 | 22.94 | 20.46 | 20.08 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | N/A | 13.58 | 13.58 | 13.58 |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | 34.64 | 55.51 | 87.60 | 87.60 |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | 4.45 | 5.51 | 6.85 | 13.80 |
| NeoGenomics, Inc. (NEO)vs › | $472.39M | N/A | 53.25 | 37.33 | 28.89 |
| NRC Health (NRC)vs › | $459.30M | 21.22 | 27.48 | 28.67 | 30.19 |
| Shoulder Innovations, Inc. (SI)vs › | $397.55M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $41.03M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
